The Global Cannabidiol (CBD) Market is anticipated to grow from USD 1,453.81 Million in 2018 to USD 17,345.80 Million by 2026 at a CAGR of 36.3% during the projection period 2019-2026. Adoption of numerous cannabis products along with the expanding customers investing in cannabis products, increasing use of cannabidiol (CBD) in medical application, and high R&D investments the pharmaceutical industry has spurred the development of the market.

The therapeutic grade segment is dominating the marketplace with the highest share of 59.90% in 2018

The product segment is segmented into food grade and therapeutic grade. The therapeutic grade segment is dominating the market with the greatest share of 59.90% in 2018. It is because of its health benefits that aid in the therapy of neuropsychiatric disorders. CBD likewise has the possible to treat other chronic disorders which is most likely to stimulate the product demand. CBD does not have any kind of synthetic ingredients or dangerous contaminants and therefore are risk-free to consume. In addition, cannabidiol (CBD) medicines has prospective to treat the chronic disorders.

In 2018, the fibromyalgia segment dominated the market with the marketplace size of USD 686.19 Million

The application segment is fractional into neurogenerative disorder, fibromyalgia, diabetes, and others. The fibromyalgia segment controlled the marketplace with the market dimension of USD 686.19 Million in 2018. It is because of the raising instances of the physiological disorder amongst people especially young adults that the demand for fibromyalgia is growing rapidly. The signs and symptoms such as prevalent musculoskeletal pain, fatigue, and other types of discomfort resulted in the fibromyalgia problem. Moreover, females has a tendency to develop fibromyalgia than are men. Many of the arising countries are legislating the use of cannabis for medicinal purposes. Cannabidiol can effectively minimize discomfort, improve sleep, in order to reduce headstrong pain for people with fibromyalgia. The cannabidiol (CBD) oil is effective to minimize the migraine and irritable bowel syndrome.

Regional Segmentation Analysis:

The market is analysed on the basis of five regions particularly North America, Europe, Asia Pacific, South America, as well as Middle East as well as Africa. The North America is controling the market with the greatest share of 42.50% in 2018. It results from the wide schedule of marijuana-derived CBD product in the region. Also, shifting consumers choices towards ingesting edibles and vapes products are more driving regional market growth. In addition, the enhancing investments for advancement and launch of brand-new product based upon the cannabidiol (CBD) is enhancing the regional growth. Asia Pacific is expected to grow rapidly due to the growing conventional use cannabidiol items in numerous food items in India, China, and Nepal. In addition, major players concentrating on the development of their existence in this region by authorizing the arrangement and collaboration with the neighborhood firms is developing new chances for cannabidiol (CBD) market in Asia Pacific region.


Competitive Analysis:

The major players of the market include Aurora Cannabis, Canopy Growth Corporation, CBD American Shaman, CV Sciences, Inc., Elixinol, Folium Biosciences, Gaia Botanicals LLC, IRIE CBD, Isodiol International Inc, NuLeaf Naturals, LLC., Pharmahemp d.o.o., and amongst lots of others. These business are adopting the strategies such as product advancements, mergers & acquisitions, current growths, joint endeavor, cooperations, and partnership to maintain their existence in the global cannabidiol (CBD) market. For example, in Feb 2018, Marijuana Company of America (MCOA) launched its hempSMART Full Spectrum Pet Drops with specially formulated product containing normally taking place CBD derived from hemp seed oil, full spectrum hemp extract, and fractionated coconut oil, in addition to a rich bacon flavor.

Customization of the Report:
The report can be customized as per client requirements. For further queries, you can contact us on or +1-201-465-4211. Our executives will be pleased to understand your requirements and offer you the best-suited reports.